In last trading session, Lumos Pharma Inc (NASDAQ:LUMO) saw 0.85 million shares changing hands with its beta currently measuring 0.69. Company’s recent per share price level of $3.27 trading at $0.82 or 33.47% at ring of the bell on the day assigns it a market valuation of $26.55M. That closing price of LUMO’s stock is at a discount of -39.14% from its 52-week high price of $4.55 and is indicating a premium of 58.1% from its 52-week low price of $1.37. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.12 million shares which gives us an average trading volume of 30.50K if we extend that period to 3-months.
For Lumos Pharma Inc (LUMO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.69 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lumos Pharma Inc (NASDAQ:LUMO) trade information
Upright in the green during last session for gaining 33.47%, in the last five days LUMO remained trading in the green while hitting it’s week-highest on Friday, 08/16/24 when the stock touched $3.27 price level, adding 5.49% to its value on the day. Lumos Pharma Inc’s shares saw a change of 2.83% in year-to-date performance and have moved 50.00% in past 5-day. Lumos Pharma Inc (NASDAQ:LUMO) showed a performance of 125.52% in past 30-days. Number of shares sold short was 0.45 million shares which calculate 9.53 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 16.5 to the stock, which implies a rise of 80.18% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 26. It follows that stock’s current price would drop -114.07% in reaching the projected high whereas dropping to the targeted low would mean a loss of -114.07% for stock’s current value.
Lumos Pharma Inc (LUMO) estimates and forecasts
Statistics highlight that Lumos Pharma Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 7.21% of value to its shares in past 6 months, showing an annual growth rate of 38.76% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 265.70% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 170k for the same. And 3 analysts are in estimates of company making revenue of 6.67M in the next quarter. Company posted 7k and 826k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 20.27% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 33.79% while estimates for its earnings growth in next 5 years are of 15.20%.
Lumos Pharma Inc (NASDAQ:LUMO)’s Major holders
Insiders are in possession of 34.80% of company’s total shares while institution are holding 26.33 percent of that, with stock having share float percentage of 40.38%. Investors also watch the number of corporate investors in a company very closely, which is 26.33% institutions for Lumos Pharma Inc that are currently holding shares of the company. WELLS FARGO & COMPANY/MN is the top institutional holder at LUMO for having 0.42 million shares of worth $1.17 million. And as of 2024-03-31, it was holding 5.129 of the company’s outstanding shares.
The second largest institutional holder is GOLDMAN SACHS GROUP INC, which was holding about 0.41 million shares on 2024-03-31. The number of shares represents firm’s hold over 5.0187 of outstanding shares, having a total worth of $1.15 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2024 , the former fund manager was holding 187.32 shares of worth $0.61 million or 2.31% of the total outstanding shares. The later fund manager was in possession of 50.83 shares on Mar 31, 2024 , making its stake of worth around $0.17 million in the company or a holder of 0.63% of company’s stock.
